AB0685 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with ankylosing spondylitis: long-term results from measure 1 and measure 2

@article{Deodhar2017AB0685SP,
  title={AB0685 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with ankylosing spondylitis: long-term results from measure 1 and measure 2},
  author={A. Deodhar and P. Conaghan and V. Strand and A. Boonen and G. Ferraccioli and F Van den Bosch and V. Bhosekar and B. Porter and K. Gandhi and S. Jugl},
  journal={Annals of the Rheumatic Diseases},
  year={2017},
  volume={76},
  pages={1293 - 1293}
}
  • A. Deodhar, P. Conaghan, +7 authors S. Jugl
  • Published 2017
  • Medicine
  • Annals of the Rheumatic Diseases
  • Background Patients (pts) with ankylosing spondylitis (AS) experience significant restrictions in work productivity and health-related quality of life (HRQoL). Secukinumab (SEC) demonstrated rapid improvements in signs, symptoms and physical functioning in pts with AS.1 Objectives To assess whether the beneficial effects of SEC on AS signs and symptoms were reflected in improvements in work productivity and HRQoL in the overall population and in TNF inhibitor (TNF)-naïve pts and pts with an… CONTINUE READING
    3 Citations
    Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives
    • PDF
    Secukinumab: A Review in Ankylosing Spondylitis
    • 5
    • PDF
    Secukinumab: A Review in Ankylosing Spondylitis
    • 22